← Back to all trials
Active Not Recruiting
NCT05575167
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
Conditions: Osteoporosis, Postmenopausal
Sex: Female
Ages: 50 Years – 85 Years
Healthy volunteers: No
Enrollment: 122
Sponsor: 424 General Military Hospital
Location: Univ. Lille, CHU Lille Lille
Summary
A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab
Eligibility Criteria
Inclusion Criteria:
• Postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia
Exclusion Criteria:
* a bone disease other than postmenopausal osteoporosis
* use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study
* creatinine clearance \
Source: ClinicalTrials.gov (NCT05575167). StuddyBuddy aggregates publicly available trial information.
